Xtacy Therapeutics Corp.

Equities

XTCY

CA98423G1072

Investment Management & Fund Operators

Market Closed - Canadian Securities Exchange Other stock markets 11:56:22 2024-04-26 am EDT			5-day change	1st Jan Change
0.045 ^CAD	0.00%		+50.00%	0.00%

Apr. 17	Xtacy Therapeutics Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI
Apr. 15	Xtacy Therapeutics Corp. Reports Earnings Results for the Full Year Ended September 30, 2023	CI

Global Wellness Strategies Inc. Auditor Raises 'Going Concern' Doubt

March 28, 2023

Global Wellness Strategies Inc. filed its Annual on Mar 29, 2023 for the period ending Sep 30, 2022. In this report its auditor, SHIM & Associates LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Xtacy Therapeutics Corp.

Xtacy Therapeutics Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023	Apr. 16	CI
Xtacy Therapeutics Corp. Reports Earnings Results for the Full Year Ended September 30, 2023	Apr. 15	CI
Xtacy Therapeutics Corp. Expands MDMA Platform Pharmaceutical Grade Psychedelic Solutions to Solve Unmet Medical Needs	Dec. 06	CI
Global Wellness Strategies Inc. will Change its Name to XTACY Therapeutics Corp	23-09-25	CI
Global Wellness Strategies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-23	CI
Global Wellness Strategies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-04-17	CI
Global Wellness Strategies Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-04-03	CI
Global Wellness Strategies Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	23-03-29	CI
Global Wellness Strategies Inc. Auditor Raises 'Going Concern' Doubt	23-03-28	CI
Global Wellness Strategies Inc. Announces Formation of Wholly Owned Pharma Subsidiary Focused on Clinical Trials	22-11-17	CI
Global Wellness Strategies Effervescent Cannabis Products Approved to Launch GWS Achieves Major Milestone Partnering with Hempsana Holdings	22-10-31	CI
Global Wellness Strategies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22-09-02	CI
Global Wellness Strategies Inc. Signs Custom Manufacturing Agreement with Hempsana Holdings	22-08-02	CI
Global Wellness Strategies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	22-05-31	CI
Global Wellness Strategies Inc. Announces Shanti Therapeutics Mdma Clinical Trial Update	22-05-12	CI
Global Wellness Strategies Inc. Announces Appointment of Sud Agarwal as the Chief Medical Advisor	22-05-09	CI
Global Wellness Strategies Inc. Announces Their Brand KaleidoMyco to Launch Their Proprietary Fizz Tablets	22-04-12	CI
Global Wellness Strategies Inc. Announces Executive Changes	22-03-01	CI
Global Wellness Strategies Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021	22-03-01	CI
Global Wellness Strategies Inc. announced that it expects to receive CAD 3 million in funding	22-02-21	CI
Global Wellness Strategies Inc. Announces the Addition of Two International Pedigreed Senior Advisors to Its Team and the Appointment of Meris Kott to the Board of Shanti Therapeutics	22-02-18	CI
Global Wellness Strategies Inc. and iNGENü Sign Supply Agreement with PharmAla Biotech to Supply GMP MDMA	22-02-10	CI
Global Wellness Strategies Inc. Reports Earnings Results for the Full Year Ended September 30, 2021	22-02-02	CI
Global Wellness Strategies Inc. Auditor Raises 'Going Concern' Doubt	22-02-01	CI
Global Wellness Strategies Inc. completed the acquisition of Shanti Therapeutics Pty Ltd from Cannvalate PTY LTD.	21-11-08	CI

Chart Xtacy Therapeutics Corp.

Duration

Period

More charts

Company Profile

XTACY Therapeutics Corp. is a Canada-based prospect generator that provides high growth companies with financial, operational, and management assistance in the fast-growing market for consumer wellness products. The Company's investment strategy is focused on the specific areas of pain, depression and mental illness. The focus of the Company is on global wellness, psychedelics, mycology, hemp and cannabidiol (CBD), healthcare-related target companies and their clinical studies and trials. By investing in techniques, such as micro-dosing using organic compounds and synthetic molecules, the Company is focusing on the research with the aim of providing wellness benefits with less side effects for people and the planet.

Sector

Investment Management & Fund Operators

Calendar

2024-05-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Investment Management & Fund Operators

	1st Jan change	Capi.
XTACY THERAPEUTICS CORP.	0.00%	1.79M
BLACKROCK, INC.	-6.03%	113B
UBS GROUP AG	-3.98%	87.91B
APOLLO GLOBAL MANAGEMENT, INC.	+20.96%	63.76B
BROOKFIELD CORPORATION	+5.29%	61.9B
BANK OF NEW YORK MELLON CORPORATION (THE)	+10.12%	42.86B
AMERIPRISE FINANCIAL, INC.	+7.95%	40.84B
3I GROUP PLC	+18.92%	34.58B
T. ROWE PRICE GROUP INC.	+5.88%	25.48B
STATE STREET CORPORATION	-5.25%	22.13B

Other Investment Management & Fund Operators